sorafenib has been researched along with Heritable Pulmonary Arterial Hypertension in 4 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 4 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Fukuda, K; Inami, T; Kataoka, M; Kimura, G; Satoh, T; Yoshino, H | 1 |
| Guignabert, C; Humbert, M; Montani, D; Weatherald, J | 1 |
| Bergot, E; Godinas, L; Guignabert, C; Humbert, M; Montani, D; Perros, F; Seferian, A; Sibille, Y | 1 |
| Baumann, C; Dahal, BK; Davie, N; Evans, S; Fairman, D; Ghofrani, HA; Grimminger, F; Kilty, I; Kojonazarov, B; Kosanovic, D; Luitel, H; Majewski, M; Phillips, P; Pullamsetti, SS; Schermuly, RT; Seeger, W; Sydykov, A; Tian, X; Wayman, C; Weissmann, N | 1 |
1 review(s) available for sorafenib and Heritable Pulmonary Arterial Hypertension
| Article | Year |
|---|---|
Tyrosine kinase inhibitors in pulmonary arterial hypertension: a double-edge sword?
Topics: Apoptosis; Benzamides; Cell Proliferation; Dasatinib; Endothelial Cells; ErbB Receptors; Familial Primary Pulmonary Hypertension; Fibroblast Growth Factor 2; Fibroblasts; Humans; Hypertension, Pulmonary; Imatinib Mesylate; Muscle, Smooth, Vascular; Myocytes, Smooth Muscle; Niacinamide; Phenylurea Compounds; Piperazines; Platelet-Derived Growth Factor; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-kit; Pulmonary Circulation; Pyrimidines; Receptor Protein-Tyrosine Kinases; Sorafenib; src-Family Kinases; Thiazoles; Treatment Outcome; Vascular Endothelial Growth Factor A | 2013 |
3 other study(ies) available for sorafenib and Heritable Pulmonary Arterial Hypertension
| Article | Year |
|---|---|
Sorafenib as a potential strategy for refractory pulmonary arterial hypertension.
Topics: Adolescent; Adult; Arterial Pressure; Dose-Response Relationship, Drug; Familial Primary Pulmonary Hypertension; Female; Heart Failure; Humans; Hypertension, Pulmonary; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Severity of Illness Index; Sorafenib; Treatment Outcome | 2017 |
Response to the article "Sorafenib as a potential strategy for refractory pulmonary arterial hypertension".
Topics: Familial Primary Pulmonary Hypertension; Humans; Hypertension, Pulmonary; Niacinamide; Phenylurea Compounds; Sorafenib | 2017 |
Effects of multikinase inhibitors on pressure overload-induced right ventricular remodeling.
Topics: Animals; Dose-Response Relationship, Drug; Familial Primary Pulmonary Hypertension; Hypertension, Pulmonary; Indoles; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyrroles; Random Allocation; Rats; Rats, Sprague-Dawley; Sorafenib; Sunitinib; Ventricular Function, Right; Ventricular Remodeling | 2013 |